03:18 , Aug 2, 2019 |  BC Innovations  |  Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
00:30 , Jul 27, 2019 |  BioCentury  |  Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
22:01 , Jul 19, 2019 |  BioCentury  |  Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
20:58 , Jul 18, 2019 |  BC Extra  |  Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877. The partnership is the second...
15:06 , Jul 15, 2019 |  BC Extra  |  Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
20:55 , Apr 1, 2019 |  BC Extra  |  Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

Bridge has parlayed a partnership with Daewoong on the South Korean biotech’s lead ulcerative colitis asset into a W31 billion ($27.2 million) series C round, which was led by returning investor UTC Investment Co. and...
16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the...
23:30 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis In vitro and mouse studies identified a hydroxamic acid-based ENPP2 inhibitor that could help treat pulmonary fibrosis. Chemical synthesis and in vitro testing in enzymatic activity assays of hydroxamic acid analogs yielded...
20:41 , Aug 18, 2017 |  BioCentury  |  Finance

IPF call options

Surprise readouts from two programs in idiopathic pulmonary fibrosis have generated over $1.4 billion in market value, and there could still be plenty of upside ahead. After market close on Aug. 7, FibroGen Inc. (NASDAQ:FGEN)...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...